



UNITED STATES  
 CONSUMER PRODUCT SAFETY COMMISSION  
 WASHINGTON, DC 20207

CPSC/OFFICE OF  
 THE SECRETARY

2000 MAY 17 P 3:42

**Vote Sheet**

**Date:** MAY 16 2000

**TO :** The Commission  
 Sadye E. Dunn, Secretary

**FROM :** Michael S. Solender, General Counsel *MS*  
 Stephen Lemberg, Asst. General Counsel *SL*  
 Harleigh Ewell, Attorney, GCRA (ext. 2217) *HE*

**SUBJECT :** Whether to Propose PPPA Rule for Oral Drugs Switched  
 from Prescription to OTC Status

This vote sheet concerns options raised by the staff's briefing package on whether the Commission should propose to require child-resistant packaging under the Poison Prevention Packaging Act of 1970, as amended, ("PPPA") for products that are subject to the Commission's rule requiring special packaging for oral prescription drugs (16 C.F.R. §§ 1700.14(a)(10)) and that are then granted over-the-counter ("OTC") status. If the Commission votes to propose such a rule, the Office of the General Counsel and the staff will prepare a notice of proposed rulemaking for the Commission's consideration.

Please indicate your vote on the following options.

- I. PREPARE A DRAFT NPR TO PROPOSE A RULE REQUIRING SPECIAL PACKAGING FOR OTC-SWITCHED ORAL PRESCRIPTION DRUGS FOR THE COMMISSION'S CONSIDERATION.

\_\_\_\_\_  
 (Signature)

\_\_\_\_\_  
 (Date)

CPSA 6 (b)(1) Cleared  
 No Mtrs/Partibirs or  
 Products Identified  
 Excepted by [Signature]  
 Rems. Notified.

II. DO NOT PROPOSE A RULE REQUIRING SPECIAL PACKAGING FOR OTC-SWITCHED ORAL PRESCRIPTION DRUGS.

\_\_\_\_\_  
(Signature)

\_\_\_\_\_  
(Date)

III. TAKE OTHER ACTION (please specify).

\_\_\_\_\_  
(Signature)

\_\_\_\_\_  
(Date)

Attachment

Comments/Instructions:

# BRIEFING PACKAGE

## PROPOSED RULE TO REQUIRE SPECIAL PACKAGING FOR ORAL PRESCRIPTION DRUGS THAT ARE GRANTED OVER-THE- COUNTER STATUS BY THE FOOD AND DRUG ADMINISTRATION



For Information Contact  
Suzanne Barone, Ph.D  
Directorate for Health Sciences  
(301) 504-0477 ext 1196

NOTE: This document has not been  
reviewed or accepted by the Commission.  
Initials Date 5/16/00

CPSA 6 (b)(1) Cleared  
No. Mrs./Prs./blrs or  
Products Identified  
Excepted by  
Notified

## TABLE OF CONTENTS

	PAGE
Executive Summary .....	3
<b>Briefing Memorandum</b>	
Background .....	4
The Role of the FDA .....	5
OTC Switches .....	5
Child-Resistant Packaging Status of Switched Drugs .....	6
History of CPSC Staff Approach to Switched Oral Drugs .....	6
Issues related to scope of the current project .....	9
Exemptions .....	11
Findings .....	12
Applicability .....	13
Effective Date .....	13
Economic Considerations .....	13
Environmental Considerations .....	14
Recommendation and Discussion .....	14
<b>TABS</b>	
TAB A Letter from Debra L. Bowen, M.D. Food and Drug Administration to Jeffrey S. Bromme, Consumer Product Safety Commission, October 7, 1998 .....	16
TAB B Ingredients and Dosages Transferred from RX-to-OTC by the FDA since 1975, compiled by the Consumer Healthcare Products Association, March 21, 2000 .....	17
TAB C Memorandum from Marcia P. Robins, EC, to Suzanne Barone, Ph.D., HS, "Economic Considerations. Proposal to Maintain Child-Resistant Packaging Requirements for Oral Prescription Drugs that have been Granted OTC status by the FDA, April 7, 2000 .....	22

## Executive Summary

The regulations of the Poison Prevention Packaging Act (PPPA) require child-resistant packaging of most oral prescription drugs. When the Food and Drug Administration (FDA) allows an oral prescription drug to be sold over-the-counter, child-resistant packaging of that drug is no longer required. The staff recommends that the Commission propose a rule to require that the child-resistant packaging requirements of an oral prescription drug continue when the active chemical is granted OTC status by the FDA. This potential rule will require that children have the same protection when the drugs are more widely available as OTC preparations as they did when the drugs were available only by prescription.

Those companies that do not need to use child-resistant packaging can provide information to the Commission, as they do currently under the PPPA oral prescription drug rule, to demonstrate that the drug products will not injure children if they are marketed in non-child-resistant packaging. The staff recommends that the Commission revoke 16 CFR 1702.16(b) to allow petitions for exemptions from child-resistant packaging to be submitted and considered by the Commission before the NDAs are approved by the FDA. This would decrease the potential financial and regulatory burdens to the drug company associated with a post-marketing package change.

Child-resistant packaging for these products is technically feasible, practicable, and appropriate. These drugs are supplied in child-resistant packaging as prescription drugs. It is anticipated that this potential rule would not create a financial burden on small companies.



UNITED STATES  
CONSUMER PRODUCT SAFETY COMMISSION  
WASHINGTON, DC 20207

Memorandum

Date MAY 16 2000

TO The Commission  
Sadye E. Dunn, Secretary

THROUGH Michael S. Solender, General Counsel ; SS  
Pamela Gilbert, Executive Director PG

FROM Ronald L. Medford, Assistant Executive Director for Hazard Identification and Reduction RLM  
Suzanne Barone, Ph D Project Manager for Poison Prevention, Directorate for Health Sciences SJB

SUBJECT Oral Prescription Drugs That Are Granted Over-The-Counter Status by the Food and Drug Administration

This memorandum presents the staff's recommendation to propose that child-resistant packaging requirements for oral prescription drugs continue when such drugs are granted over-the-counter (OTC) status by the Food and Drug Administration. The recommended rule would help ensure that children have the same protection when drugs are widely available as OTC preparations as they did when the drugs were available only by prescription.

BACKGROUND

The Poison Prevention Packaging Act of 1970 (PPPA) was established to protect children from serious personal injury or illness resulting from handling, using, or ingesting hazardous substances. Under the PPPA, the U.S. Consumer Product Safety Commission (CPSC) can require child-resistant packaging of hazardous household chemicals, including drugs. The CPSC currently requires child-resistant packaging of oral prescription medications, unless they have been specifically exempted from the packaging requirements (16 CFR § 1700.14(a)(10)). In contrast, OTC drugs, which are also called nonprescription drugs because they can be sold to consumers without a prescription from a licensed medical practitioner, are not regulated under the PPPA as a class. However, regulations have been issued to require several individual OTC products to have child-resistant packaging.

To date, 12 OTC drugs have been regulated individually under the PPPA. The drugs and the effective dates of these PPPA requirements are aspirin (1972), liquid methyl salicylate (1972), iron-containing drugs (1978), acetaminophen (1980), diphenhydramine (1984), ibuprofen (1992), loperamide (1993), lidocaine

CPSA 6 (b)(1) Cleared  
No Mfrs/Prvtlbrs  
Identified 4

(1996), dibucaine (1996), naproxen (1996), ketoprofen (1997), and minoxidil (1999)

Several of the OTC drugs listed above have been sold only as nonprescription products. However, diphenhydramine, ibuprofen, loperamide, naproxen, and ketoprofen were oral drugs available originally only by prescription. These drugs therefore required child-resistant packaging under the oral prescription drug regulation (16 CFR § 1700(a)(10)). The Food and Drug Administration (FDA) subsequently granted these drugs OTC status at specific dosage levels, thus removing them from the child-resistant packaging requirements of the oral prescription drug regulation. After each of these substances was granted OTC status, the Commission promulgated a separate regulation to require the child-resistant packaging of the drug.

## THE ROLE OF THE FDA

The FDA regulates which drugs and combinations of drugs can be sold in the United States. This includes determining which drugs can be sold directly to the consumer in OTC preparations. The primary concern of the FDA is to provide drug products to the consumer that will be safe and effective when self-administered in a proper manner. The FDA does not base granting OTC status on whether the drug would be toxic to a child if the drug is unintentionally ingested. The FDA stated in a letter to CPSC staff that "approval of an OTC switch does not in any way imply that FDA has concluded that the product does not continue to need child-resistant packaging." A copy of this letter is at Tab A.

## OTC "SWITCHES"

Since 1976, the FDA has permitted many drugs to be sold OTC. According to the Consumer Healthcare Products Association (CHPA) website, "more than 600 OTC products on the market today use ingredients or dosages available only by prescription just 20 years ago." Trade press articles speculate that this trend will continue.<sup>1</sup> A table listing 80 drugs that have been granted OTC status since 1976 compiled by the Consumer Healthcare Products Association (CHPA) is at Tab B. It should be noted that of the 80 listings in the table, 22 are different oral drugs that were previously available by prescription. The other listings are topical drugs, new uses, or new formulations for existing OTC drugs, or new approved OTC drugs that were not previously prescription products.

The intent of the current staff proposal is to maintain child-resistant packaging of oral drug products when those products are switched from prescription to OTC status by the FDA<sup>2</sup>. Therefore, oral drugs that are switched

---

<sup>1</sup> Levy, S., *Several Prescription Candidates Reported Ripe for OTC Switching*, Drug Topics, November 16, 1998, p 51

<sup>2</sup> This would not apply to topical drugs because as a class, topical prescription drugs do not require child-resistant packaging. Topical drugs, either prescription or OTC, would have to be regulated separately.

from prescription to OTC status would still be subject to a child-resistant packaging requirement.

### CHILD-RESISTANT PACKAGING STATUS OF “SWITCHED” DRUGS

To date, the Commission has required child-resistant packaging of 6 of the 22 oral prescription drugs that have been approved for OTC sale. The six OTC-switched drugs that currently require child-resistant packaging, the date of OTC approval by the FDA, and the effective date of the child-resistant packaging requirements are listed in Table 1. The other 16 drugs are discussed below.

**Table 1: Prescription Drugs Switched to OTC Status that Require Child-Resistant Packaging**

DRUG	Year OTC	Year CRP Effective
<i>Diphenhydramine HCL</i>	1982	1984
<i>Diphenhydramine monocitrate</i>	1982	1985
<i>Ibuprofen</i>	1984	1992
<i>Loperamide</i>	1988	1993
<i>Naproxen sodium</i>	1994	1996
<i>Ketoprofen</i>	1995	1997

### HISTORY OF CPSC STAFF APPROACH TO “SWITCHED” ORAL DRUGS

In the past, the staff focused primarily on ingestion data to recommend what products should be in child-resistant packaging. In the late 1970s the FDA allowed the OTC sale of several antihistamines that were previously available only by prescription. In 1982, the CPSC staff evaluated the possibility of requiring child-resistant packaging of OTC antihistamines. Ingestion data and medical literature reports were reviewed. This effort to require child-resistant packaging of all OTC antihistamines was discontinued because, at that time, limited available ingestion data showed that diphenhydramine was the antihistamine associated with several deaths and the most serious injuries to children. Diphenhydramine hydrochloride was the first OTC-switched drug to be regulated under the PPPA by CPSC. FDA permitted the monocationic salt of diphenhydramine to be sold OTC in 1982. The diphenhydramine hydrochloride packaging regulation was then amended to cover all diphenhydramine salts.

In 1984, the CPSC staff evaluated the ingestion data related to ibuprofen. Ibuprofen was granted OTC status during that year. At that time, the poisoning

data were limited and the staff did not recommend child-resistant packaging. The two companies that first marketed OTC ibuprofen used child-resistant packaging voluntarily on some package sizes. In 1989, the CPSC staff revisited ibuprofen toxicity because ibuprofen had become widely available. Not all companies were using child-resistant packaging and serious injuries to children resulted. The staff recommended child-resistant packaging for these products and the Commission issued the rule. Companies that were marketing their products in non-child-resistant packaging changed their packaging to comply.

The experience with diphenhydramine and ibuprofen resulted in a change in the staff's approach to recommendations for child-resistant packaging for "switched" OTC products. Rather than wait for deaths or injuries to children, the staff has become more proactive in recommending child-resistant packaging requirements for the OTC drugs. For the past several years the staff has focused on the potential toxicity of drugs that are going to be switched instead of waiting for poisonings to occur after the drug is released and marketed. The staff has made the evaluation of potential switched drugs the first priority. As a result, separate regulations for loperamide, naproxen, and ketoprofen were considered by the Commission shortly after OTC status for each drug was granted by the FDA.

The CPSC staff monitors FDA's activities concerning approval of switched OTC drugs. The staff attends FDA advisory panel meetings when possible, to better understand any issues about a potential drug and the likelihood of approval of OTC status by the FDA. The FDA is not bound to accept the panel's recommendations regarding OTC switches, though in most cases the FDA does. The review of the potential toxicity of the drug to young children then becomes a priority for the CPSC staff. For example, the FDA Nonprescription Drug Advisory Panel and the Arthritis Advisory Panel met jointly in July 1999 to discuss the proposed OTC switch of a current prescription drug used for muscle spasms. The CPSC staff attended this meeting and continues to follow the status of this drug. If it appears that the drug may receive OTC approval, completion of a toxicity review will become a priority for HS staff. The staff waits for FDA approval before proceeding with a review, to avoid expending the CPSC's limited resources if the FDA does not approve the OTC sale of the drug. This rulemaking would eliminate the lag between OTC approval and the requirement for child-resistant packaging.

As a result of the staff's focus on newly switched drugs, many of the earlier switched drugs have not been formally reviewed to determine if they should be in child-resistant packaging. The 16 oral prescription drugs that were switched to OTC status and do not require child-resistant packaging are listed in Table 2. The fact that these drugs do not currently require child-resistant packaging is not the result of an affirmative determination that these drugs do not need to be in child-resistant packaging to protect children. The staff has preliminarily assessed the toxicity of eight of these drugs. Based on the toxicity of these products, the staff would recommend child-resistant packaging for four of the drugs (indicated with a plus sign). Five of the antihistamine drugs identified by a question mark are

currently under preliminary review by the staff. These drugs are related in structure and activity to diphenhydramine, which currently requires child-resistant packaging.

**Table 2: Oral Prescription Drugs that Switched to OTC Status**

DRUG	Type of Drug	Toxicity	Year OTC
Brompheniramine maleate	Antihistamine	?	1976
Chlorpheniramine maleate	Antihistamine	?	1976
Pseudoephedrine HCl	Decongestant	+	1976
Pseudoephedrine sulfate	Decongestant	+	1976
Doxylamine succinate	Antihistamine	?	1978
Phenylpropanolamine HCl	Decongestant	+	1981
Dexbrompheniramine maleate	Antihistamine	?	1982
Tripolidine HCl	Antihistamine	?	1982
Pyrantel pamoate	Anthelmintic	?	1985
Chlophedianol HCl	Antitussive	?	1987
Clemastine fumarate	Antihistamine	+	1992
Dexchlorpheniramine maleate	Antihistamine	?	1992
Famotidine	H <sub>2</sub> Antihistamine	-	1995
Cimetidine	H <sub>2</sub> Antihistamine	-	1995
Ranitidine	H <sub>2</sub> Antihistamine	-	1995
Nizatidine	H <sub>2</sub> Antihistamine	-	1996

- +Toxicity of the drug is such that the staff would recommend CR packaging
- Toxicity of the drug is such that the staff would not recommend CR packaging
- ? Review of the toxicity of the drug has not been completed.

The four drugs listed that the staff would not recommend child-resistant packaging for are antihistamines used to reduce stomach acid. These drugs do not have the same toxicity associated with antihistamines used to treat cold symptoms. The staff would have recommended that the Commission exempt these drugs from the child-resistant packaging requirements, had the companies petitioned the Commission when the drugs were only available by prescription.

The staff does not recommend that the Commission retrospectively require child-resistant packaging of the 16 OTC-switched drugs listed in Table 2. Many of

these products are already in child-resistant packaging because they are sold in combination with other drugs that already require child-resistant packaging, for example pseudoephedrine with ibuprofen or an antihistamine with acetaminophen or aspirin. In addition, staff is aware of some OTC products that are packaged voluntarily in child-resistant packaging. The staff continues to evaluate these OTC drugs as time and priority permit. More staff time would be available to review these previously released products if a rule to maintain packaging on future switched OTCs is adopted by the Commission.

## **ISSUES RELATED TO SCOPE OF THE CURRENT PROJECT**

The staff recommends that this potential rule extend to oral OTC drugs that contain an ingredient that originally required a prescription. As described below, variables such as dosages, uses, new oral formulations, and combinations with other drugs should not affect the requirement for child-resistant packaging.

### **Additional Uses, Forms, and Combinations of OTC-Switched Drugs**

The FDA can approve a new usage or a new dosage form of an existing OTC product. The staff recommends that the new use or new dose automatically require child-resistant packaging even if the new use or dose was not approved when the drug was only available by prescription. Currently, a new use for an oral OTC product that is already PPPA-regulated does not affect the child-resistant packaging requirement. For example, after February 11, 1985, any oral product that contained more than the equivalent of 66 mg diphenhydramine base was required to be in child-resistant packaging. At that time, diphenhydramine was in OTC sleep aids and hay fever preparations. In 1987, when diphenhydramine was allowed by the FDA to be sold OTC as an oral antiemetic drug, no further PPPA regulation was necessary. This same focus on the drug entity itself rather than the approved usage is necessary for the recommended rule to be successful. If an oral prescription drug were granted OTC status by the FDA it would automatically require child-resistant packaging under the recommended rule. If the FDA then approved another OTC use for that same drug it would also automatically require child-resistant packaging.

The current project would not extend child-resistant packaging requirements to switched OTC products that are not oral formulations, even if they contain the same drug as an oral preparation. Formulations other than oral, such as topical preparations, or transdermal patches would still have to be regulated separately.

In some cases, after a prescription drug is approved for OTC sale by the FDA, other forms, dosages, or combinations containing that drug will also be approved for OTC sale. These combinations or forms may not have existed when the drug was available by prescription only. This current project would cover these situations if, as we recommend, any proposed rule is not limited to the specifically

switched preparation, but extends to all oral products that contain a drug that was originally switched. For example, loperamide was granted OTC status in 1988. The CPSC required the packaging of any oral product that contained more than 0.045 mg of loperamide in 1993. In 1997, the FDA approved the combination of loperamide and simethicone in an OTC product. This was never a prescription combination product. However, the combination product currently requires child-resistant packaging because the loperamide PPPA rule is not limited to the original prescription formulation. It is important that this rulemaking include all future oral OTC combinations that contain the switched drug.

### **Change in Dosage Between Prescription and OTC Drugs**

The prescription version of a drug may be available in different dosages, strengths, and forms. However, the FDA may place restrictions on the allowed level of a drug available for OTC use. Several different scenarios exist. First, the drug may be sold OTC at the lowest prescription dosage. This is true for many of the switched drugs, including the antihistamines. Second, the drug may be sold OTC at the prescription strength but the total daily allowable dose is lower for the OTC drug. This is the case for OTC loperamide. Lastly, a lower dosage may be developed for the OTC preparation. OTC ibuprofen and naproxen are examples of this.

The staff recommends that the Commission propose including any OTC oral drug containing the chemical entity that was available by prescription even if the OTC dosage is lower than the prescription strengths. This is consistent with the PPPA oral prescription drug regulation, which does not specify a dose for the individual prescription drugs. In addition, the Commission has issued rules for OTC drugs that are available at a lower dose than the prescription strength. The Commission's experience with ibuprofen and naproxen demonstrate that toxic amounts of the drugs are available even at these new lower dosages. The utility of the current potential rulemaking would decrease substantially if drugs such as ibuprofen and naproxen had to be regulated individually.

### **Identification of Switched Drugs**

If this potential rulemaking includes switched drugs and any future combination, dosage, oral formulation, etc. without individual action by the Commission as the staff recommends, it may be difficult for CPSC staff and the drug industry to identify which drugs would require child-resistant packaging. Therefore, the staff recommends that after the FDA approves an oral prescription drug for OTC sale, the CPSC publish an FR notice identifying the drug as requiring special packaging under the "OTC switched" regulation in 16 CFR § 1400.14. This would not involve rulemaking, it would merely consist of CPSC identifying products that already would require child-resistant packaging under the existing regulation.

## EXEMPTIONS

An exemption procedure exists for PPPA-regulated products that do not pose a risk of serious injury or illness to children or for which child-resistant packaging is not technically feasible, practicable, or appropriate (16 CFR § 1702). Companies petition the Commission to exempt products by submitting data, described in 16 CFR § 1702, to support either that the drug will not cause serious injury or that it is not technically possible to develop and produce child-resistant packaging for the drug product. The exemption procedure involves rulemaking. Currently, 18 oral prescription drugs (16 CFR § 1700.14(a)(10)(i)-(xx)) and several OTC formulations of aspirin (16 CFR § 1700.14(a)(1)(i)-(ii)), acetaminophen (16 CFR § 1700.14(a)(16)(i)-(ii)), and iron (16 CFR § 1700.14(a)(13)(i)-(ii)) have been exempted from the child-resistant packaging requirements.

This exemption procedure would be available to manufacturers of OTC switch products if the products continued to require child-resistant packaging when the status changed to OTC. Two issues related to the petition process for exemptions that need to be considered are staff resources and timing.

The first issue relates to the potential expenditure of staff resources to process petitions requesting exemptions of switched drugs. The staff believes that the number of exemptions that may be requested in the future for switched drugs would not be high. None of the 22 drugs that have switched to OTC status requested an exemption from the child-resistant packaging standards when they were prescription drugs. Therefore, we should not assume that the makers of the 16 switched OTC drugs that do not currently require child-resistant packaging would have petitioned for exemption if their drugs had required child-resistant packaging at the time of the switch. As stated above, many of these drugs are already marketed in child-resistant packaging, either voluntarily or because they are in combination with another PPPA-regulated substance. In addition, current child-resistant packaging is easier for adults to use because of the 1995 revisions to the child-resistant packaging test protocols. Also, companies have the option of marketing one OTC package size that is non-child-resistant, as long as it is properly labeled and other popular sizes of child-resistant OTC packaging are available (15 USC 1473).

The second issue is one of the timing of the submission of petitions for exemption. The PPPA regulations currently specify that the Commission shall deny a petition if the FDA has not approved the new drug application (NDA) (16 CFR § 1702.16(b)). Applications to switch drugs from prescription to OTC status are handled by the FDA as NDAs. Therefore, if the Commission does not grant a petition before a drug is approved, companies would have to either market in child-resistant packaging, delay marketing the approved OTC drug until the Commission acts, or request a stay of enforcement to allow marketing in non-child-resistant packaging while the Commission considers the petition.

A post-marketing change in packaging of an approved new or generic OTC drug may be more complex for the drug manufacturer than simply buying different packaging and modifying the packaging equipment. In some cases, the FDA must approve the new packaging before the drug can be marketed<sup>3</sup>. Stability testing of the product in the new package must be completed and the results submitted to the FDA for approval before the product can be marketed in the new package.

The staff recommends that 16 CFR 1702.16(b) be revoked to allow petitions to be submitted and considered by the Commission earlier in the process, before the NDAs are approved by the FDA. This would provide manufacturers with the opportunity to request an exemption from the child-resistant packaging requirements and have a decision by the Commission prior to the NDA submission and approval.

## **FINDINGS**

### **Hazard to Children**

Before issuing a rule, the Commission must find that the degree or nature of the hazard to children in the availability of these OTC drugs by reason of their packaging is such that special packaging is required to protect children from serious injury or illness from handling, using, or ingesting the drugs (15 U.S.C. 1472(a)(1)). The Commission made this finding previously for oral prescription drugs. The oral prescription drug regulation does not specify a dose for the individual prescription drugs.

The need to continue to protect children remains when oral prescription drugs are granted OTC status. A decision by the FDA to grant OTC status for a prescription drug is not determined by the lack of toxicity to a child if the drug is accidentally ingested (Tab A). The drugs have the same toxicity whether they are prescription or OTC. The issue is whether drugs switched to OTC status at a lower dosage than was available by prescription are still hazardous to young children. The Commission has previously issued rules for OTC drugs that are available at a lower dose than the prescription strength. The Commission's experiences with ibuprofen and naproxen demonstrate that toxic amounts of the drugs are available even at the lower dosages.

Another important consideration is that OTC drugs are more readily available to consumers and therefore more accessible to children. The CPSC staff concludes that the available data support the finding that child-resistant packaging is necessary to protect children from serious injury or illness from ingesting oral prescription drugs that have been granted OTC status.

---

<sup>3</sup> Guidance for Industry, Changes to An Approved NDA or ANDA. Food and Drug Administration, CMC, November 1999.

## **Technical Feasibility, Practicability, and Appropriateness**

The Commission must also find that child-resistant packaging is technically feasible, practicable, and appropriate. The Commission made these findings previously for oral prescription drugs. The change in status from prescription to OTC does not change the ability of child-resistant packaging to be made, to be mass-produced, and to maintain the shelf life of these drugs.

In some cases the same packaging can be used for the OTC product as the prescription product. However, companies must modify the labels since the FDA labeling requirements for OTC drugs are different than the prescription drug requirements. Most companies develop new packaging specifically for the OTC market because prescription drugs are typically repackaged by the pharmacist from containers of bulk drugs. Unit dose packaging is popular for the OTC market especially for drugs that are sold in limited quantities like antihistamines. Other products are sold in bottles like the anti-inflammatory drugs such as ibuprofen or naproxen. There are child-resistant designs of reclosable packaging and unit packaging that are commercially available.

The CPSC staff concludes that the available data support the finding that it is technically feasible, practicable, and appropriate to produce special packaging for oral OTC products that were originally sold by prescription.

## **APPLICABILITY**

Since the packaging of OTC-switched drugs is determined before the company submits the information requesting the "switch" to the FDA, the staff recommends that this rule only apply to OTC-switched drugs subject to a new drug application (NDA) or abbreviated new drug application (ANDA) submitted to the FDA more than 180 days after the publication of the final rule. This proposed regulation would not affect any oral prescription drug that is already approved by the FDA for OTC sale.

## **EFFECTIVE DATE**

The PPPA provides that no regulation shall take effect sooner than 180 days or later than one year from the date such final regulation is issued, except that, for good cause, the Commission may establish an earlier effective date if it finds that it is in the public interest to do so. For the reasons discussed in the preceding section, the staff recommends a 180-day effective date.

## **ECONOMIC CONSIDERATIONS**

Before issuing a rule, in addition to complying with the requirements in the PPPA, the Commission must either assess the impact of a regulation on small

entities or certify that there will not be a significant economic effect on a substantial number of small entities.

Historically, marketers of a drug that transferred to OTC status develop packaging with "shelf appeal" to attract consumers and compete with other products in the therapeutic category. The incremental costs of providing child-resistant packaging is small (\$0.005 - \$0.02) depending on the choice of packaging. In addition, child-resistant packaging is readily available. It is unlikely that this proposal will have a substantial effect on a significant number of small businesses. A more detailed discussion is at Tab C.

## **ENVIRONMENTAL CONSIDERATIONS**

A special packaging requirement will have no significant effects on the environment, since these products required child-resistant packaging before the change in status to OTC. In addition, the manufacture, use, and disposal of child-resistant packaging will present the same environmental effects as nonchild-resistant packaging.

## **RECOMMENDATION AND DISCUSSION**

The staff recommends that the Commission propose a rule to require that the child-resistant packaging requirements of an oral prescription drug continue when the active chemical is granted OTC status by the FDA. This potential rule will require that children have the same protection when the drugs are more widely available as OTC preparations as they did when the drugs were available only by prescription. The potential rule would eliminate the possibility of a drug being available in nonchild-resistant packaging for an extended time before child-resistant packaging is required. The need to continue to protect children does not diminish when oral prescription drugs are granted OTC status. A decision by the FDA to grant OTC status for a prescription drug is not determined by the lack of toxicity to a child if the drug is accidentally ingested. The drugs are still toxic, whether they are prescription or OTC.

The staff does not recommend that the rule include drugs previously switched to OTC. To the extent existing OTC-switched drugs are not already in child-resistant packaging, the staff will continue to review these drugs and where appropriate recommend that the Commission issue separate PPPA regulations for those products.

The CPSC staff believes that the number of OTC switches is likely to increase in the future. With this rule, child-resistant packaging of the switched oral drugs will be maintained without a separate evaluation of each switched product. CPSC staff resources that would have been used to review each of these drugs would be saved and could be directed towards other Commission activities.

The potential rule should extend to all future oral OTC drugs containing an ingredient that originally required a prescription even if the dosage or formulation for the OTC product differs from the original prescription drugs. The PPPA rules for ibuprofen and naproxen demonstrate the need for this provision. Without it, the utility of such a rule decreases because drugs such as ibuprofen and naproxen would still have to be regulated separately.

In order to identify the drugs that would be affected by this rule, the staff recommends that the CPSC publish an FR notice following the FDA approval of an OTC switched oral drug. This drug would then be listed under the switched regulation in 16 CFR §1700.14. Since this process would not involve rulemaking, the staff recommends that the Commission delegate to the CPSC staff the authority to publish the notice listing the drugs.

This potential rulemaking will make it easier for the drug industry to develop packaging for switched OTC drugs. Changing packaging in the post-marketing stage will be unnecessary. The industry will know that the drugs require child-resistant packaging. Those companies that do not need to use child-resistant packaging can provide information to the Commission, as they do currently under the PPPA oral prescription drug rule, to demonstrate that the drug products will not injure children if they are marketed in non-child-resistant packaging. The staff recommends that the Commission revoke 16 CFR 1702.16(b) to allow petitions for exemptions from child-resistant packaging to be submitted and considered by the Commission before the NDAs are approved by the FDA. This would decrease the potential financial and regulatory burdens to the drug company associated with a post-marketing package change.

Child-resistant packaging for these products is technically feasible, practicable, and appropriate. These drugs are supplied in child-resistant packaging as prescription drugs. It is anticipated that this potential rule would not create a financial burden on small companies.

**TAB A**



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

RECEIVED  
GENERAL COUNSEL OFFICE

Food and Drug Administration  
Rockville MD 20857

'98 OCT 14 A7:35

OCT 7 1998

Jeffrey S. Bromme, Esq.  
General Counsel  
Consumer Product Safety Commission  
Washington, DC 20207-0001

Dear Mr Bromme:

This letter responds to your inquiry regarding whether the Food and Drug Administration (FDA) uses as a condition of approval for switching orally administered drugs for human use from prescription to over-the-counter (OTC) status, a determination that a child who ingests an accidental overdose of the product would not sustain a serious injury or illness or that children would not have access to the product.

As you are aware, with some enumerated exceptions, orally administered drugs when required by law to be dispensed by prescription are subject to a special packaging standard issued by the FDA under the Poison Prevention Packaging Act of 1970 (PPPA), which is now administered by the U.S. Consumer Product Safety Commission (CPSC) 16 C.F.R. § 1700.14(a)(10). When the special packaging requirement was issued, the standard was premised on a statutory finding that special packaging is required to protect children from serious personal injury or serious illness resulting from handling, using, or ingesting orally administered prescription drug products. 15 U.S.C. § 1472(a)(1). When such drugs are switched from prescription to OTC status, that special packaging requirement no longer expressly applies.

The FDA does not condition OTC status on a determination that a child who ingests an accidental overdose of the product would not sustain a serious injury or illness or that children would not have access to the product. Approval of an OTC switch does not in any way imply that FDA has concluded that the product does not continue to require child-resistant packaging.

I hope this discussion addresses your concerns. Please contact me if you have any questions

Sincerely,

Debra L. Bowen, M.D.  
Acting Director  
Division of Over-the-Counter  
Drug Products

**TAB B**

**Ingredients & Dosages Transferred From Rx-to-OTC Status (or New OTC Approvals) by the Food and Drug Administration Since 1975**  
 March 21, 2000

<u>INGREDIENT</u>	<u>ADULT DOSAGE</u>	<u>PRODUCT CATEGORY</u>	<u>DATE OF OTC APPROVAL</u>	<u>PRODUCT EXAMPLES</u>
brompheniramine maleate	4 mg /4-6 hours (oral)	antihistamine	September 9, 1976	Dimelane (A H Robins)
chlorpheniramine maleate	4 mg /4-6 hours (oral)	antihistamine	September 9, 1976	Allerest (Pharmacruf), Chlor-Trimelton (Schering), Contac (SmithKline), Sudafed Plus (Warner-Lambert)
oxymetazoline hydrochloride	0.05% aqueous solution (topical)	nasal decongestant	September 9, 1976	Afrin (Schering), Duralong (Plough), Dristan Long Lasting (Whitehall), Neo-Synephrine-12 Hour (Bayer)
pseudoephedrine hydrochloride	60 mg /4 or 4-6 hours (oral) 240 mg max /24 hours	nasal decongestant	September 9, 1976	Sudafed (Warner-Lambert), Neo-Synephrinol (Bayer)
pseudoephedrine sulfate	60 mg /4 or 4 6 hours (oral)	nasal decongestant	September 9, 1976	Afrinol (Schering), Chlor-Trimelton (Schering)
xylometazoline hydrochloride	0.1% aqueous solution (topical)	nasal decongestant	September 9, 1976	Orrivin (Ciba)
doxylamine succinate (NDA)	25 mg single dose only (oral)	sleep-aid	October 18, 1978	Unisom (Pfizer)
hydrocortisone	0.25 to 0.50% (topical)	antipruritic (anti-itch)	December 4, 1979+	Cortaid (Upjohn), Lanacort (Combe)
hydrocortisone acetate	0.25 to 0.50% (topical)	antipruritic (anti-itch)	December 4, 1979+	Bactine (Miles), Caldecort (Pharmacruf)
acidulated phosphate fluoride rinse	0.02% fluoride in aqueous solution	dental rinse	March 28, 1980	
sodium fluoride rinse	0.05% aqueous solution (topical)	dental rinse	March 28, 1980	Fluorigard (Colgate-Palmolive)
stannous fluoride gel	0.4% gel (topical)	anticanes gel	March 28, 1980	GeiKam Gel (Colgate-Palmolive)
stannous fluoride rinse	0.1% aqueous solution (topical)	dental rinse	March 28, 1980	Stan Care (Block)
ephedrine sulfate	0.1 to 1.25% (topical)	anorectal/vasoconstrictor	May 27 1980	Pazo Ointment (Bristol-Myers)
epinephrine hydrochloride	0.005 to 0.01% (topical)	anorectal/vasoconstrictor	May 27 1980	
phenylephrine hydrochloride	0.25% (topical)	anorectal/vasoconstrictor	May 27 1980	
chlorpheniramine maleate (NDA)	12 mg /12 hours (oral timed-release)	antihistamine	July 23 1981	Triaminic 12 (Sandoz)
phenylpropanolamine hydrochloride (NDA)	75 mg /12 hours (oral timed-release)	nasal decongestant	July 23 1981	Triaminic 12 (Sandoz)
diphenhydramine hydrochloride (NDA)	25 mg /4 hours (oral)	antitussive	August 7, 1981	Benlyn (Parke-Davis)
haloprogin	1.0% (topical)	antifungal	March 23, 1982	
miconazole nitrate	2.0% (topical)	antifungal	March 23 1982	Micalin (Ortho)
diphenhydramine hydrochloride	50 mg single dose only (oral)	sleep aid	April 23 1982	Sominex 2 (Beecham), Sleep-eze 3 (Whitehall)
diphenhydramine monochlorate	76 mg single dose only (oral)	sleep aid	April 23 1982+	Excedrin PM (Bristol-Myers)
dyclonine hydrochloride	0.05 to 0.1% solution or suspension, 1 to 3 mg as lozenge	oral anesthetic	May 25 1982	Sucrets Maximum Strength (SmithKline)
dexbrompheniramine maleate (NDA)	6 mg /12 hours (oral timed-release)	antihistamine	September 3 1982	Drixoral (Schering)
pseudoephedrine sulfate (NDA)	120 mg /12 hours (oral timed-release)	nasal decongestant	September 3 1982	Afrinol Repetabs (Schering)
luprolidine hydrochloride	2.5 mg /4-6 hours	antihistamine	November 26 1982	Actidil Capsules (Warner-Lambert) Actidil Syrup and Capsules (Warner-Lambert)

+FDA approval for OTC marketing is on an interim basis pending adoption of a Final Monograph

<u>INGREDIENT</u>	<u>ADULT DOSAGE</u>	<u>PRODUCT CATEGORY</u>	<u>DATE OF OTC APPROVAL</u>	<u>PRODUCT EXAMPLES</u>
ibuprofen (NDA)	200 mg /4-6 hours (oral)	internal analgesic/ antipyretic	May 18, 1984	Advil (Whitt-hall) Nuprin (Bristol-Myers)
dexbrompheniramine maleate	2 mg /4-6 hours (oral)	antihistamine	January 15, 1985	Benadryl 25 (Warner-Lambert)
diphenhydramine hydrochloride	25-50 mg /4 6 hours (oral)	antihistamine	January 15, 1985	Acitfed (Warner-Lambert)
pseudoephedrine hydrochloride(NDA)	120 mg /12 hours (oral timed-release)	nasal decongestant	June 17, 1985	Actifed 12-hour Capsules (Warner-Lambert)
Irupridine hydrochloride (NDA)	5 mg /12 hours	antihistamine	June 17, 1985	
oxymetazoline hydrochloride (NDA)	0.025% solution/drops (topical)	ocular vasoconstrictor	May 30, 1986	Ocudear (Schering)
pyrantel pamoate	11 mg /kilo of body weight maximum dose 1 gram (oral)	anthelmintic	August 1, 1986	Pin-X (Efficon)
povidone iodine sponge (NDA)	10% (new dosage form)	antimicrobial	January 7, 1987	E-Z Scrub 241 (Deseret)
diphenhydramine hydrochloride	25 50 mg /4-6 hours (oral)	antileptic	April 30, 1987	
dexbrompheniramine maleate (NDA)	3 mg /6-8 hours (oral)	antihistamine	May 22, 1987	Drixoral Plus (Schering)
chlorphedianol hydrochloride	25 mg /6 8 hours (oral)	antitussive	August 12, 1987	
doxylamine succinate	7 5 mg - 12 5 mg /4-6 hours (oral)	antihistamine	August 24, 1987	Nyquil (Procter & Gamble)
loperamide (NDA)	4 mg , then 2 mg , 8 mg /day (oral)	antidiarrheal	March 3 1988	Imodium A D (Johnson & Johnson)
hydrogenated soybean oil and lecithin	12 4 gm. powder in 2-3 oz. water 20 minutes before gall bladder x-rays	cholecystokinetic	February 28, 1989	Lipospense (Merck)
clotrimazole (NDA)	1% lotion and cream/2 times daily	antifungal	October 23, 1989	Lotrimin AF (Schering)
permethrin (NDA)	1% cream rinse	pediculicide (head lice)	May 5, 1990	Nix (Warner-Lambert)
clotrimazole (NDA)	1% cream & 100 mg inserts	anticanidial	November 30, 1990	Gyne-Lotrimin (Schering), Mycelex-7 (Miles)
miconazole nitrate	2.0% cream and 100 mg inserts	anticanidial	March 13, 1991	Monistat 7 (Ortho)
hydrocortisone	above 0.50% to 1.0%	antipruritic (anti itch)	August 30, 1991+	
hydrocortisone acetate	above 0.50% to 1.0%	antipruritic (anti-itch)	August 30, 1991+	
clemastine fumarate (NDA)	1 34 mg /12 hours	antihistamine	August 21, 1992	Tavist-1 (Sandoz Consumer)
clemastine fumarate (in combination with phenylpropanolamine HCl) (NDA)	1 34 mg /12 hours decongestant	antihistamine/ decongestant	August 21, 1992	Tavist-D (Sandoz Consumer)
dexchlorpheniramine maleate	2 mg/4-6 hours (oral)	antihistamine	December 9, 1992	(last monograph switch)
naproxen sodium (NDA)	200 mg/4-6 hours (oral)	internal analgesic/ antipyretic	January 11, 1994	Aleve (Bayer)
pheniramine maleate with naphazoline HCl (NDA)	0.3%, 0.025% in solution	ophthalmic antihistamine/ decongestant	June 8, 1994 *	Naphcon A (Alcon) Opcon A (Bausch & Lomb) Ocuhist (Alcon)
antazoline phosphate with naphazoline HCl (NDA)	0.5%, 0.05% in solution	ophthalmic antihistamine/ decongestant	July 11, 1994	Vasocon A (Ciba)
famotidine (NDA)	10 mg, up to 20 mg/day	acid reducer	April 28, 1995	Pepcid AC (J&J Merck)
ibuprofen suspension 100mg/5ml for pediatric use (NDA)	7 5 mg/kg up to 4 times a day	internal analgesic antipyretic	June 16 1995	Children's Motrin (McNeil Consumer)
cimetidine (NDA)	200 mg up to twice per day	acid reducer	June 19, 1995	Tagamet HB (SmithKline)
ketoprofen (NDA)	12 5 mg every 4 to 6 hours	Internal analgesic	October 16 1995	Orudis KT (Whitehall-Robins) Acron (Bayer)
ranitidine (NDA)	75 mg up to twice per day	acid reducer	December 19, 1995	Zantac 75 (Warner Wellcome)

<u>INGREDIENT</u>	<u>ADULT DOSAGE</u>	<u>PRODUCT CATEGORY</u>	<u>DATE OF OTC APPROVAL</u>	<u>PRODUCT EXAMPLES</u>
butoconazole nitrate (NDA)	2 0% cream and applicators (3 days)	antifungal	December 26, 1995	Femstat 3 (Procter & Gamble)
minoxidil (NDA)	2 0% topical solution	hair grower	February 9, 1996	Rogaine (Pharmacia & Upjohn)
nicotine polacrilex (NDA)	2 mg and 4 mg gum	smoking cessation	February 9, 1996	Nicorette (SmithKline Beecham)
nizatidine (NDA)	75 mg up to twice daily	acid reducer	May 9, 1996	AXID AR (Whitehall-Robins Healthcare)
miconazole nitrate (NDA)	2 0% cream and 200 mg inserts	antifungal	April 16, 1996	Monistat 3 (Ortho)
nicotine transdermal system (NDA)	15 mg patch	smoking cessation	July 3, 1996	Nicotrol (McNeil Consumer)
clotrimazole (NDA)*	1% cream & 200 mg inserts	antifungal	July 29, 1996	Gyne-Loirin 3 (Schering-Plough)
nicotine transdermal system (NDA)	21, 14, & 7 mg patch	smoking cessation	August 2, 1996	Nicoderm CQ (SmithKline Beecham)
bentoquatam (NDA)*	5% lotion	poison ivy protection	August 26 1996	Ivy Block (EnviroDerm)
cromolyn sodium (NDA)	4% nasal solution	allergy prevention & treatment	January 6, 1997	Nasalacrom (McNeil Consumer)
tioconazole (NDA)	6 5% vaginal ointment	antifungal	February 11, 1997	Vagistat-1 (Bristol-Myers Squibb), Monistat 1 (McNeil)
loperamide/simethicone (NDA)*	2 mg loperamide, 125 mg simethicone	antidiarrheal/antigas	June 26, 1997	Imodium Advanced (McNeil Consumer)
triclosan (dentifrice) (NDA)*	0 30% triclosan/0 243% fluoride	antigingivitis	July 11, 1997	Total (Colgate-Palmolive)
ketoconazole (NDA)	1% shampoo	dandruff shampoo	October 10, 1997	Nizoral (Johnson & Johnson Consumer Products)
minoxidil (NDA)*	5 0% topical solution	hair grower	November 17, 1997	Rogaine Extra Strength for Men (Pharmacia & Upjohn)
aspirin /caffeine /acetaminophen(NDA)**	250mg/65mg/250mg	migraine	January 14 1998	Excedrin Migraine (Bristol-Myers Squibb)
ranitidine (NDA)*	75 mg (effervescent system)	acid reducer	February 26, 1998	Zantac 75 EFFERdose (Glaxo Wellcome)
miconazole nitrate (NDA)*	4 0% cream	antifungal	March 30 1998	Monistat 3 (Advanced Care Products)
terbinafine hydrochloride (NDA)	1 0% cream	antifungal	March 9 1999	Lamisil AT (Novartis)
cimetidine suspension (NDA)*	suspension	acid reducer	July 9, 1999	Tagamet HB 200 (SmithKline Beecham)
naproxen Na, pseudoephedrine HCl*	220 mg naproxen Na, 120 mg pseudoephedrine HCl	analgesic/decongestant	November 29, 1999	Aleve Cold & Sinus (Bayer Consumer Care)
ibuprofen**	200 mg	migraine	February 25, 2000	Motrin Migraine Pain (McNeil Consumer Healthcare)
ibuprofen**	200 mg	migraine	March 16, 2000	Advil Migraine Liqui-Gels (Whitehall-Robins)

DA approval for OTC marketing is on an interim basis pending adoption of a Final Monograph \* New OTC NDA - Not previously Rx \*\*New OTC indication, product previously OTC

**II Other Potential OTC Ingredients/Dosages**  
 Note CHPA Listing of Potential Switches is Based on Published Sources or Publicly Available Information

<u>INGREDIENT</u>	<u>ADULT DOSAGE</u>	<u>PRODUCT CATEGORY</u>	<u>SOURCE OR INTERIM FDA POSITION, IF KNOWN</u>
acamprosate	-----	alcoholism treatment	Mentioned as hopefully "eventually" an OTC in New York Times, July 31, 1998
acyclovir	200 mg	antiviral	Adv Crmte voted "No" on 1/12/95 for OTC management of recurrent genital herpes
albuterol sulfate	2 mg	bronchodilator	Mentioned as switch candidate in Med Ad News, Dec., 1996
alosetron	-----	irritable bowel syndrome	Mentioned as switch candidate in The Tan Sheet - January 24, 2000
astemizole	-----	antihistamine	Mentioned as "future switch" in Switch Newsletter Feb., 1996
atorvastatin calcium	-----	cholesterol-lowering agent	Asbury Park Press, July 14, 1999
<u>GREDIENI</u>	<u>ADULT DOSAGE</u>	<u>PRODUCT CATEGORY</u>	<u>SOURCE OR INTERIM FDA POSITION, IF KNOWN</u>
ithromycin	-----	antibiotic	Mentioned as switch candidate in Med Ad News Dec., 1996

beclomethasone dipropionate	nasal spray 0.042%	allergy prevention & treatment	Scheduled Adv Cmte consideration on Sept 19, 1997 - postponed
butenafine	-----	antifungal	Mentioned as switch candidate in <i>Drug Store News</i> Sept 7, 1998
celecoxib	-----	non-steroidal anti-inflammatory	Mentioned as switch candidate in <i>PRNewsWire/NewsEdge</i> Nov 9 1999
ceftirizone Hcl	-----	antihistamine	Mentioned as switch candidate in <i>Drug Topics</i> Apr 6 1998
cholestyramine	-----	cholesterol-lowering agent	FDA tentative position cholesterol-lowering agents not appropriate for OTC use
clotrimazole/betamethasone	-----	antifungal	Mentioned as switch candidate in <i>Drug Store News</i> , Sept 7, 1998
colestipol hydrochloride	-----	cholesterol lowering agent	FDA tentative position cholesterol-lowering agents not appropriate for OTC use
cyclobenzaprine HCl	5 mg	muscle spasm treatment	Discussed at NDAC/Arthritis Adv Cmte meeting on July 20 1999 More info requested
diclofenac	-----	non-steroidal anti-inflammatory	Mentioned as switch candidate in "The Tan Sheet," March 23, 1998
diflunisal	-----	non-steroidal anti-inflammatory	<i>FDC Reports</i> , November 7, 1988 p 10
docosanol	10% topical cream	antiviral for cold sores	<i>Scrip</i> Nov 5, 1999 FDA says clinical data "sufficient for approval" as new OTC
econazole nitrate	1%	antifungal	NDA pending <i>Progressive Grocer</i> April, 1995
erythromycin	-----	antibiotic	<i>FDC Reports</i> June 12, 1989, "Potential switch product" in <i>Med Ad News</i> , August 1996
etidolac	200 mg	non-steroidal anti-inflammatory	<i>FDC Reports</i> - "The Tan Sheet," Sept 30 1996, p 15
fexofenadine	-----	antihistamine	Mentioned as switch candidate in "The Tan Sheet," August 18 1997
fluconazole	-----	antifungal	Mentioned as 'future switch' in <i>Switch Newsletter</i> Feb , 1996
fluticasone propionate	nasal spray	allergic rhinitis symptoms	Mentioned as switch candidate in "The Tan Sheet," January 24 2000
fluvastatin	-----	cholesterol-lowering agent	FDA tentative position cholesterol-lowering agents not appropriate for OTC use
ibuprofen extended release	-----	non-steroidal anti-inflammatory	
loratadine	-----	antihistamine	Mentioned as 'future switch' in <i>Switch Newsletter</i> Feb , 1996
lovastatin	-----	cholesterol lowering agent	FDA tentative position cholesterol lowering agents not appropriate for OTC use
melhacarbamol	-----	muscle relaxant	Muscle relaxants discussed by Adv Cmte 3/28/95 Issue of switch unresolved
mupirocin	-----	topical antiviral	"Potential switch product" in <i>Med Ad News</i> , August, 1996
nabumetone	-----	non-steroidal anti-inflammatory	"Potential switch product" in <i>Med Ad News</i> , August, 1996
nicotine	nasal spray, oral inhaler	smoking cessation	"Near-term switch candidates" in "The Tan Sheet," May 19, 1997
nitrofurantoin monohydrate	-----	urinary tract antibiotic	"Potential switch candidate" in "The Tan Sheet" Dec 16, 1996, p 7
nystatin	-----	antifungal	Mentioned as switch candidate in <i>Med Ad News</i> , Dec , 1996
omeprazole	-----	antisecretory (heartburn)	OTC launch expected 2 <sup>nd</sup> quarter, 2001, per "The Tan Sheet," Nov 1 1999
penciclovir	-----	topical antiviral (cold sores)	Narrowly rejected by Adv Cmte 12/1/88 "Tan Sheet" reports still being pursued (5/3/99)
piroxicam	-----	non-steroidal anti-inflammatory	Mentioned as "future switch" in <i>Switch Newsletter</i> Feb , 1996
rofecoxib	-----	non-steroidal anti-inflammatory	Mentioned as switch candidate in <i>PRNewsWire/NewsEdge</i> , Nov 9 1999
sucralfate	-----	anti-ulcer	NDA pending, <i>FDC Reports</i> January 16, 1989, p 8
sulindac	300 mg /day	analgesic	<i>FDC Reports</i> April 3, 1989, p 7
sumatriptan succinate	-----	migraine treatment	Mentioned as switch candidate in "The Tan Sheet" January 24 2000
theophylline	-----	bronchodilator	Mentioned as switch candidate in <i>Med Ad News</i> Dec , 1996
<b>NO</b>	<b>ADULT DOSAGE</b>	<b>PRODUCT CATEGORY</b>	<b>SOURCE OR INTERIM FDA POSITION, IF KNOWN</b>
1011	-----	acne treatment	Mentioned as switch candidate in OTC News, June 1997

valacyclovir  
zanamivir

500 mg  
inhalant

antiviral  
influenza treatment prophylaxis

Mentioned as switch candidate in "The Tan Sheet," August 18, 1997

Mentioned as switch candidate in "The Tan Sheet " May 12, 1997, p 15

WB/ib 3/21/00 c WPPW/606M/POCCS/IO/CS/ITCH CHR

**TAB C**



UNITED STATES  
CONSUMER PRODUCT SAFETY COMMISSION  
WASHINGTON, DC 20207

**Memorandum**

Date: April 7, 2000

TO : Suzanne Barone, Ph D Project Manager, HS  
THROUGH Warren J. Prunella, AED, EC *wj*  
FROM Marcia P. Robins, EC *MPR*  
SUBJECT : Economic Considerations: Proposal to Maintain Child-Resistant Packaging Requirements for Oral Prescription Drugs That Have Been Granted OTC Status by the FDA

The Directorate for Economic Analysis reviewed the economic, small business, and environmental effects of the subject proposal. Attached are the finds of these reviews.

Attachment (s)

## **Economic Considerations: Proposal to Maintain Child-Resistant Packaging Requirements for Oral Prescription Drugs That Have Been Granted OTC Status by the FDA**

The Poison Prevention Packaging Act (PPPA) requires child-resistant (CR) packaging for all oral drugs dispensed by prescription (Rx), unless they have been specifically exempted from packaging requirements. CR packaging is provided either by the drug supplier pre-packaging the drug, or by the dispensing pharmacist repackaging the prescribed amount of the drug for the consumer. Packaging requirements can be waived based on a request by the physician prescribing the drug or by the purchaser. When over-the-counter (OTC) marketing approval for drug ingredients originally available Rx-only is granted by the Food and Drug Administration (FDA), the PPPA oral prescription drug requirements no longer apply. The ultimate packaging of a product then becomes the responsibility of the drug marketer, and the pharmacist is no longer a secondary packager.

CPSC can promulgate packaging requirements for OTC products if the Commission finds that the degree or nature of the hazard to children in the availability of such substance, by reason of its packaging, is such that special packaging is required to protect children from serious personal injury or serious illness resulting from handling, using, or ingesting such substance. The Commission made such findings for products formerly marketed as oral Rx drugs and now available OTC that contain ingredients such as ibuprofen, loperamide, naproxen, and ketoprofen. The staff recommends that the Commission propose the continuation of PPPA requirements for oral drug products containing ingredients transferred by the FDA from Rx to OTC marketing status.

### **FDA Procedures for Transferring Drugs from Rx to OTC Status**

The FDA transfers ingredients from Rx to OTC marketing status through the approval of a New Drug Application (NDA) initiated by the manufacturer and, with the concurrence of an Advisory Panel. Approvals are for specific ingredient dosages and specific therapeutic usage. An ingredient can be transferred for multiple purposes. The ingredient review program started in 1972; the first Rx/OTC transferred ingredients were marketed in 1976. An estimated 63 ingredients and dosages were transferred from 1975 to May 1996, including ingredients used in topical preparations.<sup>1</sup> No one knows exactly how many ingredients/dosages are in, or may soon enter, the transfer "pipeline." However, a July 1998 article in the trade press citing Consumer Healthcare Products Association (CHPA) data listed 28 potential transfers, including some for topical use as well as for oral use.<sup>2</sup>

---

<sup>1</sup>*Pharmaceutical and Medical Packaging News, September 1996.*

<sup>2</sup>*Drug Topics, July 20, 1998.*

## **Packaging Rx/OTC Transferred Products**

Historically, when a drug product's ingredients transfer from Rx to OTC status, the marketer provides packaging with "shelf appeal" in an effort to attract consumers and compete with other products in the therapeutic category. Marketers must choose some form of packaging but are no longer bound by PPPA requirements and can provide nonCR packaging for transferred products. The incremental cost of providing basic CR packaging is usually small (\$0.005-\$0.02) depending upon the choice of package. The cost may be somewhat higher if more elaborate packaging is provided. Marketers are required to perform one-time stability and other testing to meet FDA requirements when changes in packaging are made.

It is unlikely that packaging manufacturers would have difficulty supplying the needed CR packaging that might result from this rule. Based on past experience, there is only a relatively small number of ingredients for oral prescription drugs that would be transferred from Rx to OTC in any given year. Consequently, CR packaging for newly transferred drug ingredients is expected to be readily available for new product introductions. Moreover, because most packaging firms already produce both CR and nonCR packaging, and because the production differences between CR and nonCR packages are minimal, packaging manufacturers would, if necessary, be able to increase the relative production of CR packages within a short time.

## **Small Business Effects**

The proposal to continue PPPA requirements for ingredients transferred by the FDA from Rx to OTC marketing status will affect an unknown number of small businesses. However, as described above, packagers of products with transferred ingredients will have to choose some form of packaging. Since the incremental cost of CR packaging is minimal, and because these costs (if any) are likely to be passed on to consumers, it seems unlikely that the proposal will have a substantial effect on a significant number of small businesses.

**Preliminary Environmental Assessment of the Proposal to Maintain Child-Resistant Packaging Requirements for Oral Prescription Drugs That Have Been Granted Over-the-Counter Status by The Food And Drug Administration**

Pursuant to the National Environmental Policy Act, and in accordance with the Council on Environmental Quality regulations and CPSC procedures for environmental review, the Commission has preliminarily assessed the possible environmental effects associated with the proposed Poison Prevention Packaging Act (PPPA) packaging requirements for maintaining child-resistant (CR) packaging requirements for oral prescription drugs that have been granted over-the-counter (OTC) status by the Food and Drug Administration.

The Commission's regulations at 16 CFR Sec. 1021.5 [C] [3] state that the rules requiring special packaging for consumer products normally have little or no potential for affecting the human environment. Preliminary analysis of the impact of this proposed rule indicates that maintaining CR packaging requirements for the production of marketers of oral prescription drug ingredients under the proposed rule will have no significant effects on the environment. The continued manufacture, use, and disposal of CR packaging will not present environmental effects.